Chemerin as a Driver of Hypertension: A Consideration

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Physiology

Background:

• Chemerin (tazarotene-induced gene, TIG2; RARRES2) is an adipokine associated with obesity and elevated blood pressure.
• Existing research indicates a positive correlation between circulating chemerin levels, body mass index, visceral fat, and blood pressure.

Purpose of the Study:

• To investigate the specific relationship between chemerin and blood pressure.
• To elucidate the mechanisms by which chemerin may pathologically alter blood pressure for potential therapeutic targeting.
• To review chemerin biosynthesis, metabolism influenced by antihypertensive drugs, and its physiological roles in blood pressure regulation.

Main Methods:

• Literature synthesis and review of existing studies on chemerin.
• Dissection of chemerin biosynthesis and its interaction with antihypertensive medications.
• Analysis of chemerin's physiological effects on organs critical for blood pressure regulation (brain, heart, kidneys, vasculature, adrenal glands, sympathetic nervous system).

Main Results:

• Chemerin's role in blood pressure regulation is complex, involving multiple organ systems.
• While plasma chemerin levels correlate with blood pressure, their direct pathological relevance may be limited.
• Antihypertensive medications can influence chemerin metabolism.

Conclusions:

• Further research is needed to fully understand the mechanisms linking chemerin to blood pressure.
• Identifying knowledge gaps in chemerin biology is crucial for future investigations.
• Interdisciplinary collaboration among protein chemists, biologists, pharmacologists, and clinicians is essential to advance this field.